ArticleAdvanced materials (Deerfield Beach, Fla.)2020
Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo.
Article in Advanced materials (Deerfield Beach, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 146 citations in OpenAlex.
- RNARL: reinforcement learning-driven unified generative framework for multi-objective RNA codon design.Genome biology · 2026Article
- Enhanced Intracellular Stability and Translation Efficiency of mRNA Drugs by a 2-arm mRNA Platform.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineered targeted enhancement of translation in mammalian cell.BMC biology · 2026Article
- mRNA-based MRI contrast agent for precise diagnosis of glioma and pseudoprogression.Cell biomaterials · 2026Article
- mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.Nature biotechnology · 2026Article
- Article
- mRNA vaccines against viral pathogens: molecular design, delivery systems, and clinical applications.Frontiers in microbiology · 2026Review
- Antimicrobial peptide delivery to lung as peptibody mRNA in anti-inflammatory lipids treats multidrug-resistant bacterial pneumonia.Nature biotechnology · 2025Article
- HydraRNA: a hybrid architecture based full-length RNA language model.Genome biology · 2025Article
- Aminophosphonate-Derived Lipid Nanoparticles Enable Circular RNA Delivery for Functional Recovery after Spinal Cord Injury.Materials today (Kidlington, England) · 2025Article
- Advances and Strategies in Enhancing mRNA Cancer Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Evaluation of synthetic mRNA with selected UTR sequences and alternative poly(A) tail,Molecular therapy. Nucleic acids · 2025Article
- Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Article
- Characterization of an mRNA-Encoded Antibody Against Henipavirus.Current issues in molecular biology · 2025Article
- UTR-Insight: integrating deep learning for efficient 5' UTR discovery and design.BMC genomics · 2025Article
- Bispecific antibody targeting of lipid nanoparticles.bioRxiv : the preprint server for biology · 2024Article
- Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.Molecular therapy. Nucleic acids · 2024Article
- A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus.NPJ vaccines · 2024Article
- LPANano research · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
SARS-CoV-2 has become a pandemic worldwide; therefore, an effective vaccine is urgently needed. Recently, messenger RNAs (mRNAs) have emerged as a promising platform for vaccination. In this work, the untranslated regions (UTRs) of mRNAs are systematically engineered in order to enhance protein production. Through a comprehensive analysis of endogenous gene expression and de novo design of UTRs, the optimal combination of 5' and 3' UTR are identified and termed NASAR, which are 5- to 10-fold more efficient than the tested endogenous UTRs. More importantly, NASAR mRNAs delivered by lipid-derived TT3 nanoparticles trigger a dramatic expression of potential SARS-CoV-2 antigens. The antigen-specific antibodies induced by TT3-nanoparticles and NASAR mRNAs are over two orders of magnitude more than that induced by the FDA-approved lipid nanoparticle material MC3 in vaccinated mice. These NASAR mRNAs merit further development as alternative SARS-CoV-2 vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.